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Abstract
Background: Rift Valley fever virus (RVFV) is a mosquito-borne pathogen causing an important disease in ruminants often
transmitted to humans after epizootic outbreaks in African and Arabian countries. To help combat the spread of the disease,
prophylactic measures need to be developed and/or improved.
Methodology/Principal Findings: In this work, we evaluated the immunogenicity and protective efficacy of recombinant
plasmid DNA and modified vaccinia virus Ankara (rMVA) vectored vaccines against Rift Valley fever in mice. These
recombinant vaccines encoded either of two components of the Rift Valley fever virus: the viral glycoproteins (Gn/Gc) or the
nucleoprotein (N). Following lethal challenge with live RVFV, mice immunized with a single dose of the rMVA-Gn/Gc vaccine
showed no viraemia or clinical manifestation of disease, but mounted RVFV neutralizing antibodies and glycoprotein
specific CD8+ T-cell responses. Neither DNA-Gn/Gc alone nor a heterologous prime-boost immunization schedule (DNA-Gn/
Gc followed by rMVAGn/Gc) was better than the single rMVA-Gn/Gc immunization schedule with regards to protective
efficacy. However, the rMVA-Gn/Gc vaccine failed to protect IFNAR2/2 mice upon lethal RVFV challenge suggesting a role
for innate responses in protection against RVFV. Despite induction of high titer antibodies against the RVFV nucleoprotein,
the rMVA-N vaccine, whether in homologous or heterologous prime-boost schedules with the corresponding recombinant
DNA vaccine, only conferred partial protection to RVFV challenge.
Conclusions/Significance: Given the excellent safety profile of rMVA based vaccines in humans and animals, our data
supports further development of rMVA-Gn/Gc as a vaccine strategy that can be used for the prevention of Rift Valley fever in
both humans and livestock.
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Introduction
Rift Valley fever virus (RVFV) is a mosquito-borne pathogen
causing periodic outbreaks of disease in livestock as well as
numerous human infections and fatalities in many African
countries (reviewed in [1]). The disease tends to occur following
periods of unusually heavy rainfall which favors overgrowth of
mosquito populations from trans-ovarially infected eggs [2].
RVFV has the potential to spread to distant geographic regions.
After extensive mainland outbreaks [3,4,5,6,7,8] the disease has
since appeared in the Arabian Peninsula [9] and several Indian
Ocean islands [10,11,12,13]. This ability to cross geographical
barriers raises concerns of potential spread to RVFV-näive areas
[14]. Several promising veterinary livestock vaccines against RVF
have been developed [15,16,17], the most advanced of which is a
live-attenuated vaccine termed ‘Clone 13’ that has been licensed
for use in several countries in Africa [18]. However, there is
currently no licensed Rift Valley fever vaccine for human use.
Non-replicating, recombinant modified vaccinia virus Ankara
(rMVA) has been used widely as a vaccine antigen-delivery platform
in previous [19,20,21] and numerous ongoing clinical trials against
different infectious diseases and cancer [22,23,24,25,26,27,28].
rMVA based vaccines have an excellent safety profile and are
proficient inducers of both humoral and cellular immune responses.
Poxviruses, including vaccinia virus, are potent inducers of type-I
and II interferons and have evolved to encode soluble receptors that
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may counteract host antiviral mechanisms. Due to deletions in the
rMVA genome, the expresfsion of such antagonists is largely absent.
This fact contributes to the immunogenicity of rMVA-based
vaccines since type-I interferons (IFNa and IFNb) may act as a
link between the innate and adaptive immune system, including
antibody and T-cell responses [29,30].
DNA vaccines encoding both viral RVFV glycoproteins (Gn
and Gc) have been tested in Balb/c mice with a varying degree of
protection, from full protection without apparent clinical display
[31] to intermediate or incomplete protection [32,33]. In addition,
DNA immunization constitutes a safe and efficacious strategy for
priming immune responses against a variety of viral pathogens,
enhancing immunity of vaccines [34,35].
In this work we evaluate the immunogenicity and protective
efficacy of two rMVA-based vaccines against RVFV in BALB/c
mice; one vaccine encodes the RVFV glycoproteins (hereafter
termed ‘rMVA-Gn/Gc’) and the other the RVFV nucleoprotein
(hereafter termed ‘rMVA-N’). We assess these rMVA vaccines in
relation to recombinant DNA vaccines encoding similar RVFV
antigens and explore potential mechanisms underlying vaccine-
induced immunity using a transgenic IFNAR2/2 mouse model.
We find that a single immunization with rMVA-Gn/Gc is
sufficient for protection against lethal challenge with live RVFV
in immunocompetent mice.
Materials and Methods
Animals and ethics statement
6 to 8 weeks old BALB/c HSD-Ola H-2Kd female mice (Harlan
Ltd) or the 129Sv/Ev parental strain and transgenic 129Sv/Ev
IFNAR2/2 mice (B&K Universal) were used in the experiments
described here. All experimental procedures were approved and
supervised by the Biosafety and Bioethics Committee from
Instituto Nacional de Investigación y Tecnologı́a Agraria y
Alimentaria (INIA), following regulatory guidelines from the
European Community Council Directive 86/609/EEC.
Construction of plasmids and generation of rMVA viruses
Construction of DNA plasmids expressing the RVFV glyco-
proteins (termed pCMV-M4) and nucleoprotein (pCMV-N) has
been described previously [36,37]. The pCMV vector contains the
cytomegalovirus immediate-early promoter (CMV-IE) for initiat-
ing transcription of eukaryotic inserts and the SV40 polyadenyl-
ation signal (SV40 poly A) for processing the 39 end of the mRNA
transcripts. The rMVA-N and rMVA-Gn/Gc vaccines were
constructed by cloning the complete open reading frame of
RVFV nucleoprotein from the RVFV MP12 strain using RVFV
S-segment cDNA sequence specific primers (GeneBank accession
number DQ380154) or the mature Gn/Gc open reading frame
(termed M4 and starting at the fourth in frame ATG) using RVFV
M-segment cDNA sequence specific primers (GeneBank accession
DQ380208), respectively. The RVFV coding sequences were PCR
amplified from plasmids pXL-TOPO-N and pXL-TOPO-M1
previously described [36,37]. The PCR products were ligated to
other sequences to create in-frame fusions of the human tissue
plasminogen activator (tPA) leader at the N terminus, a T-cell H-
2Kd restricted epitope (Pb9) from Plasmodium berghei and a
monoclonal antibody recognition tag at the C terminus
(SV5Pk1tag). The inclusion of the tPA leader sequence was based
on its association with increased expression and immunogenicity of
other genes expressed in the MVA system as previously described
[38,39]. The C-terminal tag can be recognized by specific
monoclonal antibodies and consists of the amino acid sequence
IPNPLLGLD. The theoretical size for the resulting ORFs was
62.5 kDa for Gn (excluding the tpA leader sequence), 57.4 kDa
for Gc (including the pb9 and pk1 tags) and 33.2 kDa for N. The
resulting tPA/M4/Pb9/Pk1 and tPA/N/Pb9/Pk1 sequences were
then ligated into a shuttle vector, pMVA-GFP, which places the
open reading frame under the control of the vaccinia p7.5 early/
late promoter, and also includes GFP as a marker gene under the
control of the vaccinia p11 late promoter (Figure 1A). The shuttle
vector was transfected into chick embryo fibroblasts (CEF) infected
with MVA and homologous recombination allowed the shuttle
vector to recombine with the MVA genome, inserting the RVFV
open reading frames and GFP marker gene at the TK locus of
MVA. The recombinant viruses (rMVA-N and rMVA-Gn/Gc)
were plaque purified and then expanded in Doug Foster-1 (DF-1)
cells.
Western blot analysis
BHK-21cell extracts, either infected with RVFV, rMVA or
transfected with plasmids were subjected to SDS-PAGE in
Laemmli’s buffer and blotted onto nitrocellulose membranes.
Detection of viral proteins was performed using specific anti-Gn
monoclonal antibodies (mAb), Gc-specific rabbit antiserum (S.
Jäckel et al, unpublished data) or anti-N mAb [40]. Detection of
the SV5Pk1 tag epitope was performed with mAb SV5-Pk1
(Serotec).
Preparation and titration of viral stocks
All animal challenge studies were performed using the South
African RVFV isolate 56/74 [41]. The challenge virus stock was
propagated twice in BHK-21 cells and titrated by plaque assay in
Vero cell monolayers. BALB/c mouse lethal infection dose was
estimated by intraperitoneal inoculation of log10 dilutions of the
stock virus. Preparation of rMVA vaccine stocks was performed by
infection of permissive chicken embryo fibroblast (CEF) cells at
low m.o.i., the supernatant collected and the remaining cells
broken by successive rounds of freezing and thawing. The
extracellular virus and released intracellular virus were further
concentrated by centrifugation through 36% (w/v) sucrose
cushions and titers determined by routine plaque assay in DF-1
cell monolayers.
Author Summary
Rift Valley fever (RVF) is an important disease of ruminants
that affects most African and Arabian Peninsula countries
where domestic livestock is the basis for subsistence in
rural areas. The disease is caused by a bunyavirus that can
be transmitted by close contact with infected animals or
through the bite of infected mosquitoes thus facilitating
the spread of the virus. Safer and practical methods to
control virus spread are demanded in order to prevent
both human and animal disease after disease outbreaks.
The efficacy of a recombinant modified poxvirus vector
(the vaccinia modified Ankara virus (rMVA)) and/or DNA-
based vaccines in a mouse infection model has been
investigated. A single immunization with a rMVA encoding
the virus envelope glycoproteins provided sufficient
immunity to protect mice against a lethal dose of RVFV.
The immune mechanisms underlying the protection were
also investigated. A number of specific immune CD8+-T
cells could be activated in the presence of at least three
different glycoprotein epitopes. On the other hand, the
protective effect of the vaccine was found only in immune
competent mice since in mice lacking IFN-type-I responses
the vaccine was not efficient.
Efficacy of a MVA-vectored RVFV Vaccine
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Experimental vaccination and RVFV challenge of mice
Groups of 5–7 mice were vaccinated with different vaccine
constructs and schedules as summarized in Table 1. 107 plaque-
forming units (pfu) of rMVA were administrated intraperitoneally
in 200 ml volumes, while 100 mg of plasmid DNA vaccines were
administered intramuscularly in 100 ml volumes. All booster doses
were administered two weeks after the first vaccination. Fifteen
days after the last immunization mice were bled and inoculated
i.p. with 103 pfu of the pathogenic RVFV 56/74 strain [41]. This
strain had been isolated from a cow after 3 passages in chicken
embryo cells and 7 passages in MDBK cells. To monitor viremia,
50–100 ml blood samples were taken at days 3, 6, 10 and 13 days
after RVFV challenge. The mice were maintained under
observation up to day 23 post challenge. During the course of
the experiment all mice were housed in a BSL-3 containment area
with food and water supplied ad libitum. Clinical signs including
ruffled fur, hunched posture, reduced activity or conjunctivitis
were monitored for three weeks after RVFV challenge. Viremia
was monitored by RT-PCR and virus isolation.
Histopathological examination
All dead or culled animals were subjected to histopathological
analysis. Liver, spleen, kidney and brain tissue samples were
collected and fixed with 10% formaldehyde in phosphate-buffered
saline (PBS), embedded in paraffin and sectioned at 4 mm. Hema-
toxylin and eosin technique was used for histological studies and
the avidin-biotin peroxidase complex (ABC) technique used for
immunohistochemical detection of specific viral nucleoprotein
antigen in liver and brain samples using the anti-nucleoprotein
mAb F1D11 [40]. Scores were assigned according to the degree
and extent of observed pathology. For liver samples: +3 = massive
destruction of hepatic architecture associated with an intense (+3)
nucleoprotein staining; +2 = severe hepatocellular necrosis with
occasional intranuclear bodies accompanied of mixed inflamma-
tory infiltrates; +1 = moderate hepatic necrosis in discrete areas
usually stained with anti-N antibody. For spleen samples pathology
was categorized according to varying levels of necrosis found in the
germinal centers (GCN), lymphoid cell depletion (LD) and
hyperplasia (HP).
Analysis of peptide specific T-cell stimulation
A selection of class-I restricted H2-K(D)d epitopes on the RVFV
Gn, Gc and N primary sequence was performed using available
prediction software (immunepitope.org). Peptides were selected on
the basis of their highest theoretical affinity score. Peptides with
overlapping sequences displaying similar affinity were selected on
the basis of their highest predicted proteasomal degradation score.
Peptides were synthesized to 95% purity in 5 mg/ml batches by
conventional techniques (Proteogenix). The number of IFN-c
Figure 1. Construct design and analysis of the expression of recombinant MVA viruses. (A) Schematic representation of the plasmid
shuttle vector used for the generation of the recombinant rMVA indicating the 59 and 39 sequences flanking the RVFV glycoprotein and/or
nucleoprotein ORFs. The plasmid derived from pSC11. (B) Expression of Gn and Gc glycoproteins and nucleoprotein N assessed by western blot of
rMVA infected BHK21 cell extracts immunoblotted with mAb 84a anti-Gn or a rabbit polyclonal serum anti-Gc. (C) Detection of nucleoprotein N
expression in rMVA-N and RVFV (MP12 strain) infected cultures by mAb 2B1. (D) Detection of expressed polypeptides in rMVA-N and rMVA-Gn/Gc
infected BHK21 cells using the anti-V5 tag mAb.
doi:10.1371/journal.pntd.0002309.g001
Efficacy of a MVA-vectored RVFV Vaccine
PLOS Neglected Tropical Diseases | www.plosntds.org 3 July 2013 | Volume 7 | Issue 7 | e2309
secreting T cells in the spleens of naı̈ve, immunized, or RVFV-
challenged mice was tested by ELISPOT assay. Briefly, 96-well
MAIPS45 Immobilon-P filter plates (Millipore) were coated with
1 mg/ml of anti- IFN-c capture antibody AG-18/RA-6A2 (BD).
Following overnight incubation at 4uC, the wells were washed three
times with RPMI 1640 medium and blocked with complete
medium supplemented with 10% fetal calf serum for 1 hour at
37uC. 56105 splenocytes/ml were seeded onto 96-well plates with
RPMI medium in the presence of 1 mM of each peptide and
incubated for 18 hours at 37uC in the presence of 5% CO2. The
plates were then washed extensively with distilled water and PBS
and incubated with 1 mg/ml of anti- IFN-c biotinylated mAb
R46A2 (BD) for 2 hours at room temperature. Afterwards, plates
were washed with PBS and 50 ml of peroxidase-labeled streptavidin
at a 1/500 dilution in PBS added to each well and incubated at
room temperature for 1 hour. Spots were visualized by the addition
of 3-amino-9-ethylcarbazole substrate (BD ELISPOT AEC sub-
strate set) and counted under magnification lens. Control wells with
medium alone or with phytohemagglutinin (Sigma Chemical Co.) at
a final concentration of 5 mg/ml were also included.
Quantification of absolute levels and functional activity
of IFN-a/b
Levels of biologically active IFN-a/b in serum were determined
using a Vesicular Stomatitis virus (VSV Indiana strain) L929 cell
cytopathic effect bioassay. L929 cells grown in multi-well plates
were incubated for 24 hours with serial 2-fold dilutions of pooled
sera from immunized or naı̈ve mice and subsequently infected
with 100 TCID50 of VSV. Three days after infection the cells were
fixed and stained with 10% formaldehyde, 0.3% crystal violet.
Serum IFN-a/b titers were expressed as the dilution resulting in a
50% inhibition of infection. Quantification of serum IFN-a was
assessed using a commercial mouse IFN-a ELISA (PBL Interferon
Source). Known concentrations of mouse interferon were used to
generate a standard curve to correlate optical densities with
interferon concentration. The sensitivity limit of the assay was
estimated in (25 pg/ml)
Detection of epitope-specific CD8+ T-cell responses by
ICCS
Mice, either vaccinated with rMVA or plasmid DNA, were
sacrificed at day 7 post immunization and their spleens were
harvested for analysis by intracellular cytokine staining (ICCS)
assay. A total of 106 splenocytes were stimulated with 1 mg/ml of
the selected peptides for 6 hours in RPMI 1640 supplemented
with 10% fetal calf serum and containing brefeldin A (5 mg/ml) to
increase the accumulation of IFN-c in the responding cells. After
stimulation, cells were washed, stained for the surface markers,
fixed, permeabilized and stained intracellularly using appropriate
fluorochromes. To analyze the adaptive immune responses, the
following fluorochrome-conjugated antibodies were used: CD4-
FITC, CD8-PerCP and IFNc-PE. All antibodies were from BD
Biosciences. Data were acquired by FACS analysis on a
FACSscalibur (Becton Dickinson) and were analyzed with FlowJo
(Tree Star 7.6.5 software).
RVFV neutralization assay
Sera from vaccinated mice were heat-inactivated at 56uC for
30 minutes and serially diluted (two-fold or three-fold, starting a
dilution of 1:20 in DMEM medium containing 2% fetal bovine
serum, mixed with an equal volume (50 ml) of medium containing
46103 pfu of a viral stock (RVFV-MP12 strain). After one hour of
incubation at 37uC, this mixture was added to Vero cell
monolayers seeded in 96-well plates. After 3 days at 37uC in the
presence of 5% CO2, cells were fixed and stained with a solution
containing 2% crystal violet in 10% formaldehyde. The neutral-
ization titer of each serum sample was defined as the reciprocal of
the highest dilution of serum where a 50% of neutralization was
observed relative to controls.
Detection of RVFV antibodies
RVFV nucleoprotein specific antibodies were detected by
ELISA as described previously [37]. Briefly, viral antigen from
RVFV strain MP12 infected cell cultures was added to 96-well
plates pre-coated with rabbit anti-RVFV hyperimmune serum.
Table 1. Morbidity, mortality and antibody responses in BALB/c mice immunized with DNA and/or rMVA vaccines.
Vaccine group Morbiditya Mortalityb Neutralizing antibodies
c N-ELISAd
Prechallenge Postchallenge Prechallenge Postchallenge
pCMV-M4 (2X) 5/7 (17) 2/7 1.4960.48 (7/7) 2.7460.39 nd nd
pCMV-M4 + MVA-Gn/Gc 2/7 (6) 2/7 0.8160.94 (3/7) 2.6560.67 nd nd
MVA-Gn/Gc 0/7 (0) 0/7 1.560.05 (7/7) 2.9360.26 nd nd
pCMV-N (2X) 3/7 (4) 3/7 nd 2.8160.55 0.9660.15 nd
pCMV-N + MVA-N 6/7 (13) 2/7 nd 2.4160.27 1.3860.43 1.8760.07
MVA-N (1X) 6/6 (9) 6/6 nd - 0.2460.14 -
MVA-N (2X) 5/5 (14) 2/5 nd nd 1.1160.05 1.5660.03
MVA-Gn/Gc + MVA-N 1/7 (3) 1/7 1.560.05 (4/7) 1.9860.47 0.7260.3 1.0760.27
Non-vaccinated control 7/7 (5) 6/7 nd nd 0.3860.13 1.76
MVA control 6/6 (7) 4/6 0.097 (0/7) nd 0.1860.02 2.90*
pCMV control 4/4 (5) 4/4 0.097(0/4) - 0.1160.04 -
a: Sick mice/total mice. Numbers in parenthesis indicate cumulative days showing clinical display.
b: Dead mice/total mice.
c: Mean 6 SD log10 titers based on a 50% cytopathic effect reduction; in parenthesis, seroconverted mice/total mice.
d: Mean 6 SD ELISA OD450 serum titers at 1/80 dilution.
nd: not done.
*only one mouse serum was available for testing.
doi:10.1371/journal.pntd.0002309.t001
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This serum captures efficiently RVFV nucleoprotein antigen, but
not RVFV glycoproteins, at the dilutions used in ELISA. Serial
dilutions of sera from immunized mice were added to wells and the
immuno-complexes detected with anti-mouse-IgG-HRPO labeled
antibody. Bound conjugate was detected using TMB (3,39,5,59-
tetramethyl-benzidine) Liquid Substrate, Supersensitive (Sigma)
for 10 min, followed by one volume of stopping solution (3N
H2SO4). Optical densities were measured at 450 nm (OD450).
Cut-off ELISA was set to two-fold the OD450 value of a pre
immune pooled mouse sera.
Statistical analysis
The log rank (Mantel-Cox) test was used for survival analysis
following RVFV challenge. Individual ELISPOT values were
determined by subtracting background values obtained after
stimulation with media only and log10 transformed for analysis.
Data from each vaccination group were analyzed using a
randomized block analysis of variance. Dunn’s and Tukey’s post
hoc tests were used for multiple comparisons among groups. All
analysis was done using the GraphPad 5.0 software (San Diego,
CA). Differences were significant when p values ,0.05.
Results
Expression of RVFV antigens in rMVA infected cells
The expression of recombinant RVFV antigens was assessed by
western blot of infected BHK-21 cell extracts using antibodies
specific for RVFV glycoproteins Gn and Gc, the RVFV
nucleoprotein N and the SV5 tag (Figure 1B). Both rMVA viruses
expressed RVFV N and Gc polypeptides of a slightly higher size
than those of MP12, according to their theoretical mass. The high
intensity of the anti-V5tag immunoblotting signal suggested that
the RVFV nucleoprotein N was expressed more efficiently than
glycoprotein Gc (Figure 1D). In contrast, the Gn glycoprotein was
also detected but at a lower molecular mass than the one expressed
in BHK-21 cell extracts infected with RVFV-MP12, potentially
indicating differences in post-translational processing of the Gn
glycoprotein in the rMVA-Gn/Gc vaccine construct as compared
to wild type RVFV.
Assessment of vaccine immunogenicity and efficacy in
BALB/c mice
We assessed the immunogenicity and protective efficacy of
several DNA and rMVA vaccination schedules, summarized in
Table 1, following challenge with 103 pfu of live RVFV strain 56/
74, a dose that ensures close to 100% mortality in BALB/c mice.
First, we evaluated vaccine constructs encoding the Gn/Gc viral
glycoproteins in three groups of 7 mice each: one group was
immunized with rMVA-Gn/Gc only, one with the recombinant
DNA vaccine pCMV-M4, and one immunized with both vaccines
in a heterologous prime-boost regimen (that is, pCMV-M4
followed by rMVA-Gn/Gc). Groups of unvaccinated mice
(n = 7), vaccinated with empty MVA (n = 6) or with empty pCMV
plasmid (n = 4) were used as controls.
Mice immunized with a single dose of the rMVA-Gn/Gc
vaccine mounted a modest RVFV neutralizing antibody response
and were fully protected against clinical disease and viremia
(Table 1 and Figure 2A). The RVFV neutralizing antibody titers
observed in the pCMV-M4-only group were comparable to those
induced by the single dose rMVA-Gn/Gc regimen. Despite this,
five of the seven mice in the pCMV-M4-only group displayed
clinical signs upon RVFV challenge (ruffled fur, hunched-like
posture and hypothermia), with two dying at 4 and 6 days post-
challenge, respectively.
Among seven mice included in the heterologous pCMV-M4-
rMVA GnGc vaccination regimen only two displayed clinical signs
of illness, dying shortly afterwards in spite of detectable RVFV
neutralizing antibodies in their serum. Four of the five surviving
mice had no detectable RVFV neutralizing antibodies (Table 1).
However, survival analysis revealed no statistically significant
difference between mice with and those without detectable RVFV
neutralizing antibodies (Figure 2A).
Next, we evaluated immunogenicity and efficacy of vaccine
constructs encoding the RVFV nucleoprotein in five groups of
mice: one group (n = 6) was immunized with a single dose of
rMVA-N, one group (n = 5) with two doses of rMVA-N, one group
(n = 7) with two doses of pCMV-N, one group (n = 7) immunized
with both vaccines in a heterologous prime-boost regimen (that is,
pCMV-N followed by rMVA-N) and a final group (n = 7)
immunized with rMVA-Gn/Gc and rMVA-N in a prime-boost
regimen. Groups of unvaccinated mice and immunized with
vectors with no insert were used as controls (Table 1).
With the exception of mice vaccinated with a single rMVA-N
dose, all mice vaccinated with a nucleoprotein-based vaccine,
whether vectored by rMVA or DNA, mounted an antibody
response against the RVFV nucleoprotein as detected by ELISA
(Table 1). Though anti-N antibodies are not neutralizing, partial
protection in experimental mouse models has been consistently
observed following immunization targeted at the RVFV nucleo-
protein [32,33,36]. In keeping with these previous studies, all but
the single dose rMVA-N regimen conferred partial protection to
RVFV challenge (Table 1 and Figure 2B). The mean viremia titers
were comparable across groups (Figure 2C), though the onset and
duration of clinical signs of illness differed markedly among the
groups. Two mice from the homologous prime-boost pCMV-N
group displayed clinical signs as early as 3 days post-challenge with
a third mouse displaying clinical signs at 10 days post-challenge.
Onset of clinical signs in the group receiving the heterologous
prime-boost regimen (that is, pCMV-N followed by rMVA-N) was
observed as from 7 days post-challenge. Mice in the homologous
prime-boost rMVA-N group also exhibited a delay in onset of
clinical signs relative to unvaccinated controls. However, mice in
the single dose rMVA-N group, which also lacked detectable anti-
N antibodies, showed clinical signs as from 4 days post-challenge
and all succumbed to the infection (Table 1 and Figure 2B).
Finally, only one of seven mice immunized with both the rMVA-
GnGc and rMVA-N vaccines displayed clinical signs of illness
(Table 1). All sera from convalescent mice, whether immunized
with Gn/Gc or N-based vaccines, had increased neutralizing titers
indicative of anamnestic responses (Table 1).
Together, these data suggest that immunization with rMVA-
Gn/Gc alone is sufficient to induce full protection in BALB/c
mice upon a lethal RVFV challenge. Nevertheless, the different
onset times and outcomes in morbidity observed among the
various Gn/Gc and N-based vaccination regimens tested suggests
that the mechanism underlying vaccine-induced immunity to
RVFV may not be solely attributable to the induction of RVFV
neutralizing antibodies. Since T-cells would be expected to play a
major role in viral clearance we next assessed the extent to which
induction of T-cell responses varied among vaccinated mice.
Analysis of T-cell responses
Several 9-mer peptides derived from Gn/Gc and N primary
sequence and predicted to be class-I MHC restricted (Tables 2 and
3) were used in an ex vivo IFN-c ELISPOT assay (see Materials and
Methods). The Gn peptide #4 (SYAHHRTLL) was previously
identified as MHC-I restricted [42]. On the other hand, peptides
#13 (SYKPMIDQL) and #14 (GGPLKTILL), included here, are
Efficacy of a MVA-vectored RVFV Vaccine
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the first MHC-I restricted epitopes identified to date on the Gc
sequence. As a positive control, the nucleotide sequence from the
well-characterized CTL epitope pb9 (SYIPSAEKI) from Plasmo-
dium berghei [43] was included in frame at the 39end of both the
RVFV nucleoprotein and glycoprotein open reading frames as
shown in Figure 1A (also see Materials and Methods). To check if
any of the predicted peptides were able to stimulate CD8+-T cells,
two mice were inoculated intraperitoneally with one dose of 107
pfu of either rMVA-N or rMVA-Gn/Gc. Splenocytes harvested at
7 days post-immunization were stimulated for 18 hours with 5 mg/
ml of each peptide.
Both mice immunized with the rMVA-Gn/Gc vaccine
displayed IFN-c secreting cells in response to peptides #4, #13
and #14 (Figure 3A). Negligible responses were found for the rest
of the assayed Gn/Gc peptides. Similarly, none of the epitopes
selected from the RVFV nucleoprotein were able to induce IFN-c
secretion upon stimulation, in spite of the clear response induced
by the pb9 control peptide, indicating that the rMVA expressed N
protein was also efficiently processed through the class-I pathway
for antigen presentation (Figure 3B).
We next tested whether the observed RVFV glycoprotein-specific
peptides were able to induce also the activation of T-cell responses in
mice immunized with plasmid DNA alone or in combination with
MVA. As shown in Figure 4, the mice vaccinated with either a single
or a booster dose of rMVA-GnGc induced consistent T-cell
responses in the ELISPOT assay. Mice that were boosted
intraperitoneally with 104 pfu of RVFV-MP12 15 days post rMVA
GnGc vaccination showed also similar T-cell responses. Mice that
were immunized with a single dose of pCMV-M4 also mounted T-
cell responses against peptides #4 and #13, albeit lower that the
levels induced by the single rMVA-Gn/Gc vaccination. Neverthe-
less, these responses were clearly increased following a booster dose
of rMVA-Gn/Gc to the pCMV-M4 group.
Identification of CD8+ T-cells
In order to confirm whether the class-I restricted peptides
stimulating ELISPOT T-cell responses were indeed recognized by
CD8+ T cells, an intracellular cytokine staining assay (ICCS) was
performed. Among mice vaccinated once with rMVAGn/Gc a
significant percentage of the whole CD8+ T cell population
expressed IFN-c in response to peptides #4, #13 and #14 but not
in the presence of the non-stimulator peptide #15 (Figure 5A).
This percentage was not increased in mice receiving a booster
dose of rMVAGn/Gc (Figure 5B). While DNA vaccination
(either single or two dose administration) was not able to
trigger significant glycoprotein specific CD8+T cell stimulation
(Figure 5C), the heterologous prime-boost (pCMV-M4 followed by
Figure 2. Survival curves and viremia upon RVFV lethal challenge in vaccinated mice. Survival curves of mice vaccinated with
glycoprotein (A) or nucleoprotein (B) based-DNA or MVA constructs upon RVFV challenge. (C) Scatter dot representation of viremia titers of individual
mice from each vaccine groups measured 3 days post viral challenge. Mean 695% confidence intervals are shown. The limit of detection of the assay
is indicated by the dotted line.
doi:10.1371/journal.pntd.0002309.g002
Efficacy of a MVA-vectored RVFV Vaccine
PLOS Neglected Tropical Diseases | www.plosntds.org 6 July 2013 | Volume 7 | Issue 7 | e2309
rMVA-Gn/Gc) was sufficient to trigger CD8+ T cell stimulation
(Figure 5D), although this was restricted to peptides #4 and #14
and at lower levels than those observed for rMVA-Gn/Gc
immunization alone or with a booster dose. Strikingly, a booster
dose of RVFV MP12 strain in mice immunized with rMVA-Gn/
Gc did not suffice to stimulate Gn or Gc peptide-specific CD8+T
cells (data not shown), in spite of the T-cell responses observed
with this vaccine regime in the ELISPOT assay. Presence of
peptide stimulated IFN-c secreting CD4+ T cells were also
analyzed but no detectable staining was achieved (not shown).
Role of type I IFN response in the protective capacity of
rMVA vaccines
Since the rMVA virus has lost several genes encoding soluble
receptors, it is unable to efficiently counteract host’s innate
immune responses. Therefore, upon rMVA infection the levels of
systemic IFN-a/b should raise temporarily allowing a window for
cytokine detection. To test whether immunization of rMVA-Gn/
Gc was indeed inducing the expression of these cytokines, sera
from mice were taken at different times post-immunization and
tested for the presence of IFN-a. An increase in the level of IFN-a
was clearly detected, peaking at 6 hours post-immunization and
spanning for at least for 24 hours (Figure 6A, left). We also tested
whether the serum levels of this cytokine were biologically active to
prevent propagation of an interferon sensitive virus such as
Vesicular stomatitis virus (VSV). A peak of antiviral activity was
observed around 6 hours post immunization, decreasing after-
wards (Figure 6A, right). Since the timing of IFN-a detection was
coincidental, the observed antiviral activity could be attributed at
least in part to the effect of IFN- a.
Table 2. List of predicted class-I-restricted GnGc ORF peptides used in the study.
Peptide # 9-mer sequence Position in ORF H-2 haplotype(s) (predicted)
1 LYRALKAII 73–81 K
d
2 PPHKKRVGI 106–114 D
d
3 TYAGACSSF 183–191 K
d
4 SYAHHRTLL 205–213 K
d
5 CSHANGSGI 434–442 K
d, Db
6 LVLGNPAPI 658–666 D
b
7 SYASACSEL 686–694 K
d
8 CGGWGCGCF 818–826 D
b, Dd
9 CFNVNPSCL 825–833 D
b
10 SCLFVHTYL 831–839 K
d
11 SGSNSFSFI 898–406 K
d
12 ESPGKGYAI 907–915 D
d
13 SYKPMIDQL 955–963 K
d
14 GGPLKTILL 1154–1162 D
d
15 LYVALSIGL 1165–1173 K
d
doi:10.1371/journal.pntd.0002309.t002
Table 3. List of predicted class-I-restricted nucleoprotein ORF peptides used in the study.
Peptide # 9-mer sequence Position in ORF H-2 haplotype(s) (predicted)
1 NYQELAIQF 3–11 K
d
2 AQAVDRNEI 13–21 K
d, Db
3 RGNKPRRMM 64–72 D
d
4 EGKATVEAL 78–86 D
d
5 EALINKYKL 84–92 D
b
6 EGNPSRDEL 94–102 D
d
7 WLPVTGTTM 125–133 D
d, Db
8 SFAGMDVPS 148–156 K
d
9 YLLQFSRVI 172–180 K
d, Db
10 FTQPMNAAV 196–204 K
d
11 NAAVNSNFI 201–210 D
b
12 SHEKRREFL 210–218 D
d
doi:10.1371/journal.pntd.0002309.t003
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Figure 3. Detection of peptide-specific T-cell responses by interferon-c ELISPOT in rMVA vaccinated mice. Cellular immune responses
in mice immunized with rMVA-N (A) or rMVA-Gn/Gc (B) measured by ELISPOT upon individual peptide stimulation of splenocytes. Values represent
mean 6 standard deviation (SD) of spot forming units (SFU) using spleen cells from two mice immunized with a single intraperitoneal dose of each
rMVA. Peptides are numbered sequentially according to their position on their respective ORFs (see Tables 2 and 3). Data were transformed by
subtraction of background (medium only) values obtained with no peptide incubation. Phytohemagglutinin (PHA) was used as a non-specific
positive control for cell cytokine expression. A peptide corresponding to the pb9 T-cell epitope was used as recombinant antigen-specific positive
control.
doi:10.1371/journal.pntd.0002309.g003
Figure 4. Cellular response against glycoprotein peptides in mice upon different vaccine combinations. Mean 6 SD log SFU values
obtained in spleen cells from mice immunized with different vaccine combinations. Naı̈ve, non-immunized mice were used as negative controls.
Peptides 4, 13 and 14 were selected on the basis of their ability to stimulate Gn and Gc specific T-cell responses. Peptide 15 was used as a non-
stimulator peptide to measure the background of the assay. The pb9 peptide was used as a specific positive control for rMVA vaccinated mice. The
plots show data from three independent experiments. Statistical significance was calculated by one-way analysis of variance (ANOVA) transforming
ELISPOT counts to log10 to limit the range of variation found among individual mice. Asterisks indicate the level of significance of each group when
compared to the MVA-GFP control group using Dunn’s post hoc test (* = p,0.05; ** = p,0.001; *** = p,0.0001).
doi:10.1371/journal.pntd.0002309.g004
Efficacy of a MVA-vectored RVFV Vaccine
PLOS Neglected Tropical Diseases | www.plosntds.org 8 July 2013 | Volume 7 | Issue 7 | e2309
Since IFN-a/b modulates the induction of subsequent adaptive
responses, including CD8+T cell specific immune responses, we
also tested the role of these cytokines in the protection elicited by
the rMVA-Gn/Gc vaccine. 129Sv/Ev IFNAR2/2 mice and
129Sv/Ev wild type mice were immunized intraperitoneally with
107 pfu of rMVA-Gn/Gc vaccine and challenged with a lethal
dose of RVFV 56/74. The level of prechallenge neutralizing
antibody titers ranged between 1/20 and 1/40 for both groups of
mice respectively, similar to those obtained in the BALB/c model.
While 8 out of 9 wild-type 129 mice survived the challenge, only
one out of 7 IFNAR2/2 mice survived the challenge (Figure 6B).
Moreover, the protective effect was glycoprotein-specific and not
solely due to the IFN type I induction since 129Sv/Ev wild type
mice vaccinated with a control rMVA expressing an irrelevant
antigen (GFP) did not survive the challenge. These data emphasize
the important role of the innate immune response in the shaping of
subsequent adaptive responses.
Pathological findings
Most mice used in the challenge study were subjected to
pathological examination. Mice could be classified into three
distinct groups based on pathological findings and independent of
vaccination regimen (Table 4). First, all mice dying before 8 dpi
showed pathology indicative of an acute onset hepatitis with
intense viral replication in liver characterized by massive hepatic
necrosis that correlated with intense staining by immunohisto-
chemistry using anti-N mAb F1D11 [40]. Splenic lymphoid
depletion of varying severity, including the presence of necrotic
cells and cellular debris in germinal centers, was also consistently
observed in these mice.
Second, a group of mice that survived longer (9 to 12 days post
challenge) did not show acute hepatitis but had affected spleen
areas with different degrees of lymphoid depletion. The cause of
death of these mice remains unclear since most of the mice that
survived the challenge also displayed similar spleen alterations
although in a few cases brain areas showed gliosis as a distinct
feature. Finally a third group of surviving mice either did not show
any particular pathology or very mild affectation was observed in
spleen in the form of lymphoid depletion. Two of these mice
showed very mild viral antigen staining in the liver and other three
mice displayed gliosis in brain, in one of them it was found
associated to viral nucleoprotein staining.
Discussion
Previous reports have shown that DNA plasmid constructs
encoding mature RVFV glycoproteins (Gn/Gc) protected BALB/
c mice from a virulent RVFV challenge, showing full protection
without apparent clinical signs [31]. In contrast, the protection
achieved in our study was not complete though close to 75%.
Figure 5. ICCS quantification of CD8+T cells stimulated by glycoprotein-specific peptides. The graphs depict percentages of interferon
secreting CD8+T cells (mean 6 SD from two mice) of Balb/c mice vaccinated with rMVA-Gn/Gc single dose (A), rMVA-Gn/Gc prime and boost (B), DNA
(pCMV-GnGc (M4)) prime and boost (C) and DNA prime and rMVA-Gn/Gc boost (D). One-way ANOVA p values are shown for each group to indicate
significant group variation (p,0.05). Peptide #15 was included as a negative (non stimulator) control. Asterisks indicate the level of significance of
each group when compared to control peptide #15 with Tukey’s post hoc test (* = p,0.05; ** = p,0.001; *** = p,0.0001).
doi:10.1371/journal.pntd.0002309.g005
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Nevertheless, our data are consistent with the ability of DNA
vaccines encoding RVFV glycoproteins to confer protection in
mice after a virulent RVFV challenge, although we did observe
clear clinical display in BALB/c mice. These differences in
mortality and morbidity with previous studies could be explained
by the lower number of immunizations (two vs three) and/or the
i.m saline delivery method used for vaccination, perhaps less
efficient than gene gun delivery in terms of eliciting protective
immune responses (saline-DNA immunization raises a predomi-
nantly Th1 response with mostly IgG2a antibodies, while gene gun
DNA immunization produces a predominantly Th2 response with
mostly IgG1 [44]). This is also true for DNA immunization using
RVFV glycoprotein Gn as immunogen [42]. Our initial aim was
to improve the efficiency of a DNA vaccine approach by testing
the option of using plasmid DNA encoding both RVFV
glycoproteins to prime immune responses following by a booster
dose with a recombinant MVA vector expressing the same
antigen. Interestingly, MVA expressed Gn showed differences in
size compared to that of MP12 that could not be attributed to
differential glycosylation, cell type or MVA encoded proteolytic
activities (data not shown). Therefore, further work will be
required to establish the molecular basis for this difference.
DNA/MVA heterologous prime-boost strategy has been shown to
enhance the levels of T-cell responses for some intracellular
pathogens [45,46]. In our hands a combined heterologous DNA
prime-rMVA-Gn/Gc boost reduced the previously observed
morbidity in DNA-only vaccinated mice after a lethal challenge,
although titers of neutralizing antibodies were not consistently
raised in all mice (as those achieved with two serially administered
plasmid doses). Moreover, some of the mice in which no
neutralizing antibodies were detected were able to survive the
challenge. Although the level of neutralizing antibodies detected
was rather low, the lack of a good correlation between protection
and induction of neutralizing antibodies was suggestive of other
immune mechanisms responsible for the level of protection
afforded. Though the overall protection achieved by the DNA-
only or prime-boost approaches was higher that the observed in
control groups, statistical significance (p#0.05) was not reached
when compared with the MVA control group (log-rank test
p = 0.0889; df = 2; x2 = 4.841) On the other hand, the observation
that a single ip administration of rMVA-Gn/Gc achieved higher
protection levels than a DNA/MVA prime boost indicated that
the immune consequences of both vaccines were nor additive nor
synergistic when triggering glycoprotein-specific protective im-
mune responses. In contrast, an enhancement of anti-N antibody
responses was achieved by DNA/MVA prime boost when
compared to vaccination with DNA or MVA-N alone. Perhaps
the nature, subcellular location and synthesis of the vaccine
Figure 6. Role of functional type I IFN response in the protection elicited by rMVA-Gn/Gc. (A) Detection of IFN-a in 129Sv/Ev mice
vaccinated with a single dose of rMVA-Gn/Gc vaccine. Kinetics of ELISA IFN-a levels (A) and antiviral activity (B) in pooled sera from immunized mice.
(B) Survival curves upon RVFV lethal challenge in vaccinated 129Sv/Ev wt (C) or IFNAR2/2 mice (D). The mice were vaccinated with a single dose
administration and challenged as described. Statistical significance was considered when p,0.05 as determined by the log rank (Mantel-Cox) test.
doi:10.1371/journal.pntd.0002309.g006
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Table 4. Summary of the pathological findings in challenged mice.
Days to
death Mouse ID Vaccine group HN LD GCN HP TN BG
N antigen
(liver)
3 6 control +++ ++ +
3 5 control +++ +++ ++ ++ ++
3 2 control +++ ++++ ++ ++
4 5 DNA GnGc (2X) +++ ++ +++ ++
4 4 control +++ ++++ ++ +++
4 2 MVA N (1X) +++ ++++ +++ +++
4 5 DNA GnGc +MVA GnGc +++ +++ +++ +++
3 5 DNA N (2X) +++ ++ ++ +++
5 7 control +++ ++++ +++ +++
5 1 control +++ ++++ +++ +++
5 4 DNA N (2X) +++ ++++ +++ +++
6 6 DNA GnGc (2X) +++ ++ ++ +
7 1 MVA N (1X) nd nd nd nd
8 5 MVA N (1X) +++ +++ +++ +++
9 7 DNA N +MVA N ++ ++ 2
9 4 DNA N +MVA N nd nd nd +/2
9 4 MVA N (1X) + ++ 2
10 3 DNA GnGc +MVA GnGc ++++ 2
10 6 MVA GnGc + MVA N + +/2
11 7 DNA N (2X) ++ 2
11 3 MVA N (1X) ++++ ++ 2
12 6 MVA N (1X) ++ ++ 2
19 3 DNA GnGc (2X) ++ 2
19 7 DNA GnGc (2X) ++ ++ 2
19 4 DNA GnGc (2X) ++++ ++++ 2
19 2 DNA GnGc (2X) + 2
19 1 DNA GnGc (2X) ++++ ++ ++ 2
19 2 DNA N (2X) + 2
19 2 DNA GnGc +MVA GnGc 2
19 1 DNA N +MVA N + + ++* 2
19 6 DNA N +MVA N + 2
19 2 DNA N +MVA N 2
19 5 DNA N +MVA N + 2
19 3 DNA N +MVA N 2
19 1 MVA GnGc + + 2
19 4 MVA GnGc ++ 2
19 2 MVA GnGc + MVA N ++ 2
19 3 control ++ ++ 2
24 7 DNA GnGc +MVA GnGc +++ +/2
24 1 DNA GnGc +MVA GnGc +++ 2
24 4 DNA GnGc +MVA GnGc +++ 2
24 6 DNA GnGc +MVA GnGc + 2
24 5 MVA GnGc + +/2
24 2 MVA GnGc + 2
24 6 MVA GnGc 2
24 7 MVA GnGc ++ 2
24 3 MVA GnGc ++ 2
24 3 DNA N (2X) ++ 2
24 6 DNA N (2X) 2
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antigen and delivery method used greatly influences the outcome
of immune responses. The mechanism of protection of anti-N
immune responses (or other non-neutralizing antibody responses)
may be related to mechanisms such as antibody-dependent cell-
mediated cytotoxicity (ADCC) or complement-dependent cyto-
toxicity (CDC). Consequently, infected cells coated with anti-N
antibodies complexed with presented N antigens or peptides,
become a target for ADCC or CDC [47]. Influenza virus
conserved internal nucleoprotein promotes heterosubtypic immu-
nity due to antibodies against the NP involving CD8+T cells in an
antibody dependent manner [48] and mice immunized with an
ubiquitinated form of the RVFV nucleoprotein displayed higher
levels of anti-N antibodies and antigen-specific T-cell responses
[49]. Recent data confirmed the RVFV nucleoprotein as a potent
human CD8+ T cell antigen [50].
Measurement of the viral RNA loads in blood by RT-qPCR
showed that all non-viremic mice vaccinated with rMVA-Gn/Gc
had higher Ct values than the viremic mice from the other vaccine
groups (not shown), suggesting the potential of rMVA-Gn/Gc to
induce close to sterile immunity. Nonetheless, other inoculation
routes distinct to the ip route (eg intradermal/intramuscular)
might be also tested, perhaps improving antigen presentation and
allowing reduction in the virus titer needed for immunization.
Therefore, one of the conclusions of this study is that the
expression of the RVFV glycoprotein components by means of an
attenuated poxvirus vector (MVA) is a valid strategy for
development of a successful vaccine approach. Recently, other
authors have shown that attenuated vaccinia viruses (VACv)
expressing RVFV glycoproteins GnGc alone or in combination
with human IFN-c [51] protected CBA mice upon two vaccine
administrations. However, after a single dose vaccination the
survival rates were 50% and 10% respectively. In our hands, a
single vaccination with rMVA-Gn/Gc was sufficient to induce
higher protection levels after lethal challenge in BALB/c mice as
well as in 129Sv/Ev mice. These discrepancies may be related
either with the mouse strain used or the blocking of IFNa/b
responses by VACv soluble receptors. In MVA the product of the
B18R gene, coding for an IFN a/b binding protein is absent
[52,53], therefore functional levels of this cytokine are detected in
sera from mice vaccinated with rMVA-Gn/Gc as early as 6 hours
post vaccination. This difference is of particular importance since
the role of IFN a/b in preventing viral infection is not limited only
to the induction of an antiviral state but it has also important
effects on the induction of adaptive immune responses. Type-I
IFNs may exert direct effects on professional antigen presenting
cells (APCs) by licensing them towards antigen processing and
cross-presentation as well as through direct stimulation of CD8+T
cells [30]. Direct stimulation of CD8+ T cells pre-activate this cell
population to respond much faster to MHC-I restricted antigens
[54]. Our data are in good agreement with these observations
since impaired IFN responses (in IFNAR2/2 mice) completely
abolished the protective effect of the vaccine. Other authors have
shown a similar effect when treating immunized mice with anti
IFN-a antibodies [55], therefore impairing temporarily the
signaling through IFNAR. Although we have no evidence of
glycoprotein specific CD8+-T cells becoming directly activated by
MVA induced IFN-a/b, a subset of these cells responded
specifically to glycoprotein Gn and Gc peptide sequences. It
would be interesting to know whether in the absence of IFN
response the peptide stimulation of CD8+T cells occurs similarly.
We have shown previously that DNA vaccination with plasmid
pCMV-M4 protects IFNAR2/2 mice from lethal RVFV chal-
lenge [36]. In contrast, the same glycoprotein antigens delivered
by means of a MVA vaccine are not able to protect this strain of
mice upon challenge. Therefore the vaccine delivery method used
appears to greatly influence the outcome. It is noteworthy to
mention that CD8+T cell responses could be more efficiently
primed in IFNAR2/2 mice than in wt mice upon DNA
vaccination [56]. Taken together this emphasizes a potential
involvement for CD8+-T cells in protection against RVFV.
Finally, the induction of T-cell responses to the well-character-
ized CD8+ T cell peptide pb9 was consistently higher when this
epitope was fused to the viral nucleoprotein rather than to the
glycoprotein sequence. This fact indicates that the viral nucleo-
protein is efficiently processed intracellularly either within the
MVA-infected cell or after APC uptake. Moreover, N cell uptake
would be favored since the N protein is found abundant in the
supernatant of infected or transfected cells [40]. The fact that the
response of pb9 predominates over the predicted epitopes in the N
sequence may be due to the absence of other MHC-I epitopes in
the N polypeptide. More work is needed to determine whether the
RVFV nucleoprotein ORF carries also immune relevant MHC-I
restricted epitopes. On the other hand, the glycoprotein-pb9
responses elicited were consistently lower than those of the
glycoprotein specific peptides. This was somewhat unexpected
since pb9 is a potent CTL stimulator. One possible explanation is
that the T-cell responses towards the Gn or Gc peptides are
immunodominant over the response induced by pb9 or, perhaps,
the proper processing of pb9 for presentation is impaired. In any
case the identified T-cell epitopes will be a very interesting tool for
the rationale design of novel RVFV vaccines and to understand
the role of CD8+T cells in protection.
Table 4. Cont.
Days to
death Mouse ID Vaccine group HN LD GCN HP TN BG
N antigen
(liver)
24 1 DNA N (2X) + 2
25 7 MVA GnGc + MVA N 2
25 1 MVA GnGc + MVA N 2
25 3 MVA GnGc + MVA N 2
25 5 MVA GnGc + MVA N 2
25 4 MVA GnGc + MVA N + 2
HN = hepatic necrosis; LD = Spleen lymphoid depletion; GCN = necrosis in germinal centers; HP = splenic hyperplasia; TN = tubular necrosis in kidney; BG = brain gliosis
(*associated with viral antigen). Liver pathology was categorized from massive (+++) to moderate (+). Spleen pathology was ranked as severe (++++), intense (+++),
moderate (++) or mild (+). Immunohistochemistry for viral N antigen detection; intense (+++), moderate (++), mild (+), weak (+/2).
doi:10.1371/journal.pntd.0002309.t004
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